DK0703926T3 - Rekombinante disulfidstabiliserede polypeptidfragmenter med bindingsspecificitet - Google Patents

Rekombinante disulfidstabiliserede polypeptidfragmenter med bindingsspecificitet

Info

Publication number
DK0703926T3
DK0703926T3 DK94921956T DK94921956T DK0703926T3 DK 0703926 T3 DK0703926 T3 DK 0703926T3 DK 94921956 T DK94921956 T DK 94921956T DK 94921956 T DK94921956 T DK 94921956T DK 0703926 T3 DK0703926 T3 DK 0703926T3
Authority
DK
Denmark
Prior art keywords
stabilized
binding specificity
molecules
polypeptide fragments
disulfide
Prior art date
Application number
DK94921956T
Other languages
English (en)
Inventor
Ira H Pastan
Byungkook Lee
Sun-Hee Jung
Ulrich Brinkmann
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK0703926T3 publication Critical patent/DK0703926T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK94921956T 1993-06-14 1994-06-14 Rekombinante disulfidstabiliserede polypeptidfragmenter med bindingsspecificitet DK0703926T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/077,252 US5747654A (en) 1993-06-14 1993-06-14 Recombinant disulfide-stabilized polypeptide fragments having binding specificity
PCT/US1994/006687 WO1994029350A2 (en) 1993-06-14 1994-06-14 Recombinant disulfide-stabilized polypeptide fragments having binding specificity

Publications (1)

Publication Number Publication Date
DK0703926T3 true DK0703926T3 (da) 1999-05-25

Family

ID=22136984

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94921956T DK0703926T3 (da) 1993-06-14 1994-06-14 Rekombinante disulfidstabiliserede polypeptidfragmenter med bindingsspecificitet

Country Status (10)

Country Link
US (3) US5747654A (da)
EP (1) EP0703926B1 (da)
JP (1) JP3474574B2 (da)
AT (1) ATE169932T1 (da)
AU (1) AU682705B2 (da)
CA (1) CA2164984C (da)
DE (1) DE69412614T2 (da)
DK (1) DK0703926T3 (da)
ES (1) ES2124419T3 (da)
WO (1) WO1994029350A2 (da)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
JPH11513669A (ja) * 1995-10-13 1999-11-24 アメリカ合衆国 ジスルフィド安定化抗体フラグメントを含む免疫毒素
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7541034B1 (en) 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
DE19721700C1 (de) * 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6519003B1 (en) 1998-03-26 2003-02-11 Eastman Kodak Company Camera with combination four-way directional and mode control interface
ATE403154T1 (de) * 1999-04-13 2008-08-15 Wilex Ag Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor
CA2374398C (en) 1999-05-27 2011-03-15 Ira Pastan Immunoconjugates having high binding affinity
WO2000075162A1 (en) * 1999-06-07 2000-12-14 Mirus Corporation A compound containing a labile disulfide bond
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US7118745B1 (en) 1999-09-27 2006-10-10 The Regents Of The University Of California Engineering antibodies that bind irreversibly
CA2385888A1 (en) * 1999-09-27 2001-04-05 The Regents Of The University Of California Engineering antibodies that bind irreversibly
EP1282722B1 (en) * 1999-10-15 2011-06-15 Avatar Medical, L.L.C. Stabilized proteins
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
JP4439808B2 (ja) 2000-06-05 2010-03-24 アルター・バイオサイエンス・コーポレーション Ｔ細胞レセプター融合体および結合体ならびにそれらの使用方法
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
JP2005512161A (ja) * 2001-03-12 2005-04-28 ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム ペプチドおよびタンパク質の立体配座アンサンブルの列挙およびリガンド親和性分析のためのコンピュータベースのストラテジー
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
DE60234193D1 (de) * 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
ES2239246T3 (es) 2001-08-31 2005-09-16 Avidex Limited Receptor soluble de celulas t.
AU2003209886A1 (en) * 2002-03-14 2003-09-22 Qlt Inc. Cancer associated araf1 protein kinase and its uses
EP1561759B9 (en) * 2002-10-11 2009-08-26 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
US20040101929A1 (en) * 2002-11-22 2004-05-27 Chi-Yao Chang Expressing mammalian protein complexes in fish
US7820787B2 (en) * 2003-01-23 2010-10-26 The Regents Of The University Of California Multi-functional antibodies
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
ATE532793T1 (de) * 2003-07-03 2011-11-15 Avatar Biotechnologies Inc Verfahren zur herstellung von molekülen mit verminderter immunogenität
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ATE468356T1 (de) 2003-11-25 2010-06-15 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
EP1710255A4 (en) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
WO2005056603A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
US7247443B2 (en) * 2004-03-17 2007-07-24 University Of Hawaii Sensor constructs and detection methods
JP4799405B2 (ja) * 2004-04-09 2011-10-26 中外製薬株式会社 細胞死誘導剤
ATE475669T1 (de) * 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
WO2006106903A1 (ja) * 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
EP1927367A4 (en) * 2005-05-18 2009-08-12 Univ Tokushima NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
EP2311854B1 (en) 2005-07-29 2013-04-17 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
DK2197903T3 (da) * 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletioner i domæne ii af pseudomonas-eksotoksin a, der reducerer nonspecifik toksicitet
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2719924C (en) * 2008-04-11 2017-10-03 Philip Tan Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
JP5501439B2 (ja) * 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
EP2435473B1 (en) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011003780A1 (en) 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
JP5795765B2 (ja) 2009-09-11 2015-10-14 アメリカ合衆国 低減した免疫原性を有する改良型シュードモナス（Ｐｓｅｕｄｏｍｏｎａｓ）外毒素Ａ
EP4134095A1 (en) 2009-09-15 2023-02-15 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
AU2011305476B2 (en) 2010-09-21 2016-12-01 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP2654790B1 (en) 2010-12-22 2019-02-06 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
US9624291B2 (en) 2011-03-17 2017-04-18 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
EP2502934B1 (en) * 2011-03-24 2018-01-17 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
KR20140036216A (ko) 2011-05-06 2014-03-25 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 메소텔린을 표적화하는 재조합 면역독소
AU2012268013B2 (en) 2011-06-09 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
US9206240B2 (en) 2011-09-16 2015-12-08 The United States of America, as represented by the Secretary, Department of Helath and Human Services Pseudomonas exotoxin A with less immunogenic B cell epitopes
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
WO2014009465A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9671405B2 (en) 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
CN104797599A (zh) 2012-11-05 2015-07-22 全药工业株式会社 抗体或抗体组合物的制备方法
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
EP2992010B1 (en) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
WO2014205187A1 (en) 2013-06-20 2014-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
EP3027649B1 (en) 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
CN105873953A (zh) 2013-11-04 2016-08-17 格兰马克药品股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
WO2015073878A1 (en) 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
CN111057151B (zh) 2014-01-06 2022-05-03 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
EP3553087A1 (en) 2014-01-08 2019-10-16 The Board of Trustees of the Leland Stanford Junior University Targeted therapy for lung cancer
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3126389A1 (en) 2014-04-02 2017-02-08 F. Hoffmann-La Roche AG Method for detecting multispecific antibody light chain mispairing
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
ES2899890T3 (es) 2014-06-30 2022-03-15 Altor Bioscience Corp Moléculas basadas en IL-15 y métodos de uso de las mismas
JP2017520575A (ja) 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
ES2847203T3 (es) 2014-08-01 2021-08-02 The Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Detección y tratamiento de herpesvirus bovino
PL3215528T3 (pl) 2014-11-06 2020-01-31 F.Hoffmann-La Roche Ag Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
AU2016258115A1 (en) 2015-05-06 2017-11-23 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
SI3356411T1 (sl) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecifična protitelesa, specifična za PD1 in TIM3
WO2017055399A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Cellular based fret assay for the determination of simultaneous binding
US11340219B2 (en) 2016-03-17 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-pY1235-MET immunological binding reagent
US10865230B2 (en) 2016-05-27 2020-12-15 Altor Bioscience, Llc Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
KR20190091264A (ko) 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
AU2018213718B2 (en) 2017-01-26 2022-08-25 Zlip Holding Limited CD47 antigen binding unit and uses thereof
AU2018231170B2 (en) 2017-03-06 2020-07-16 Altor Bioscience Corporation IL-15-based fusions to IL-12 and IL-18
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
IL268527B2 (en) 2017-04-05 2024-03-01 Hoffmann La Roche Bispecific antibodies bind to PD1 and LAG3 specifically
KR20200090742A (ko) 2017-08-28 2020-07-29 알토 바이오사이언스 엘엘씨 Il-7 및 il-21에의 il-15 기반 융합
JP7145895B2 (ja) 2017-09-01 2022-10-03 四川科倫博泰生物医薬股▲フン▼有限公司 組換え二重特異性抗体
CA3089333C (en) 2018-03-26 2023-10-10 Altor Bioscience Llc Anti-pdl1, il-15 and tgf-beta receptor combination molecules
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
EP3801771A1 (en) * 2018-06-04 2021-04-14 Diatheva S.r.l. Anti-cd99 diabody or igg antibody and uses thereof
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
KR20220004979A (ko) 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
US20210139585A1 (en) 2019-05-21 2021-05-13 Novartis Ag Cd19 binding molecules and uses thereof
CA3140142A1 (en) 2019-05-21 2020-11-26 Novartis Ag Trispecific binding molecules against bcma and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
AU2020334237A1 (en) 2019-08-19 2022-02-10 Universität Basel Cell therapy methods
CA3162748A1 (en) 2019-11-25 2021-06-03 Akeso Biopharma, Inc. Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
EP4077363A1 (en) 2019-12-20 2022-10-26 F. Hoffmann-La Roche AG Il-37 fusion proteins and uses thereof
US20230128499A1 (en) 2020-03-27 2023-04-27 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
JP2023548529A (ja) 2020-11-06 2023-11-17 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
EP4240494A1 (en) 2020-11-06 2023-09-13 Novartis AG Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN112500491B (zh) 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
AU2022206061A1 (en) 2021-01-06 2023-07-06 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
CN115068603A (zh) 2021-03-12 2022-09-20 中山康方生物医药有限公司 含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途
CN115192718A (zh) 2021-04-14 2022-10-18 中山康方生物医药有限公司 抗cd47的单克隆抗体及其用途
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
KR20240038008A (ko) 2021-07-28 2024-03-22 에프. 호프만-라 로슈 아게 암 치료 방법 및 조성물
CN114181310B (zh) 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
WO2023194807A2 (en) * 2022-04-04 2023-10-12 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CA3208473A1 (en) 2022-06-22 2023-12-22 Akeso Biopharma, Inc. Pharmaceutical composition and use thereof
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JP3105898B2 (ja) * 1988-04-16 2000-11-06 セルテック リミテッド 組換えｄｎａタンパクの製造方法
EP0861893A3 (en) * 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
CA2120153C (en) * 1991-09-30 2006-06-06 Ira Pastan Recombinant immunotoxins

Also Published As

Publication number Publication date
US6147203A (en) 2000-11-14
JPH09502862A (ja) 1997-03-25
CA2164984A1 (en) 1994-12-22
AU682705B2 (en) 1997-10-16
AU7246494A (en) 1995-01-03
DE69412614T2 (de) 1998-12-24
US5747654A (en) 1998-05-05
DE69412614D1 (de) 1998-09-24
ATE169932T1 (de) 1998-09-15
US6558672B1 (en) 2003-05-06
ES2124419T3 (es) 1999-02-01
WO1994029350A3 (en) 1995-02-02
EP0703926A1 (en) 1996-04-03
JP3474574B2 (ja) 2003-12-08
CA2164984C (en) 2009-02-17
EP0703926B1 (en) 1998-08-19
WO1994029350A2 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
DK0703926T3 (da) Rekombinante disulfidstabiliserede polypeptidfragmenter med bindingsspecificitet
BR9807464A (pt) Conjugado, composição, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método para produzir um polipeptìdeo e polipeptìdeo.
DK368588A (da) Bindingsmolekyler med en enkelt polypeptidkaede
CA2122732A1 (en) Multivalent antigen-binding proteins
UA40621C2 (uk) Моноклональне антитіло, гібридомна клітинна лінія, поліпептид (варіанти), фрагмент днк (варіанти), фармацевтична композиція, спосіб одержання моноклонального антитіла
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
KR950700419A (ko) 단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins)
KR900700134A (ko) Il-2 수용체-특이적 키메릭 항체
RS20050834A (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO1998033919A3 (en) Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use
ES2124224T3 (es) Metodo para escrutar genotecas recombinantes.
WO2007126798A3 (en) Regulated expression of recombinant proteins from adeno-associated viral vectors
BR9809778A (pt) Polinucleotìdeo isolado, vetor de expressão, peptìdeo ou polipetìdeo isolado, anticorpo, processo para produzir o mesmo, fragmentos de anticorpos, anticorpos de cadeia única ou anticorpos humanizados, e, anticorpo anti-idiotìpico.
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
CA2068222A1 (en) Monoclonal antibodies
WO2003008626A3 (en) Novel human nucleic acids encoding a pantothenate kinase and methods of use
Adetugbo Spontaneous somatic mutations. Structural studies on mutant immunoglobulins.
WO1991015582A3 (en) Purified rap gaps, rap gap sequences, and uses thereof
ATE317851T1 (de) Polypeptide mit aminosäuresequenzen aus dem n- terminalen bereich von gp116 von cytomegalovirus und deren verwendung bei der diagnostik, prophylaxe und therapie
HUP9902713A2 (hu) Ráksejteket specifikusan detektáló antigénkötő fragmensek, a fragmenseket kódoló nukleotidok és alkalmazásuk rák megelőzésére, és kimutatására
PT93394A (pt) Processo para a preparacao de celulas de hibridonas produzindo anticorpos ligaveis a moleculas de adesao intercelular